<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01099527</url>
  </required_header>
  <id_info>
    <org_study_id>2009-02-041</org_study_id>
    <nct_id>NCT01099527</nct_id>
  </id_info>
  <brief_title>A Trial of RAD001/Capecitabine in Refractory Gastric Cancer</brief_title>
  <official_title>A Phase I/II Trial of RAD001/Capecitabine in Refractory Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Capecitabine is an oral fluoropyrimidine that has been shown to be effective in the treatment
      of metastatic gastric and colorectal cancer patients. On the basis of capecitabine-based
      chemotherapy which is accepted as a standard regimen in gastric cancer, we will perform the
      phase I/II study with all-oral regimen of RAD001 with capecitabine for these refractory
      gastric cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine maximum tolerated dose (MTD) in phase I</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess response rate in phase II</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Metastatic Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus (RAD001) dose escalation of capecitabine, everolimus
Capecitabine dose escalation of capecitabine, everolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus (RAD001)</intervention_name>
    <description>dose escalation of capecitabine, everolimus</description>
    <arm_group_label>Everolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>dose escalation of capecitabine, everolimus</description>
    <arm_group_label>Everolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically proven gastric cancer patients

          2. Adequate organ function as defined by the following criteria:

             A. Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase (SGOT))
             and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase (SGPT)) ≤ 2.5
             x local laboratory upper limit of normal (ULN), or AST and ALT less than or equal to 5
             x ULN if liver function abnormalities are due to underlying malignancy B. Total serum
             bilirubin ≤ 3.0 mg/dL C. Absolute neutrophil count (ANC) ≥1500/µL D. Platelets
             ≥100,000/µL E. Hemoglobin ≥9.0 g/dL (may be transfused or erythropoietin treated) F.
             Serum calcium ≤12.0 mg/dL G. Serum creatinine ≤1.5 x ULN

          3. Patients with CNS metastasis must have stable neurologic function without evidence of
             CNS progression within 8 weeks

          4. Patients who have failed to at least two previous cytotoxic chemotherapy for advanced
             gastric cancer (adjuvant treatment will be counted as one regimen if received &lt; 12
             months from the start of experimental treatment)

          5. At least one measurable lesion by RECIST criteria

          6. ECOG PS 0-2

          7. Patients with informed consent

        Exclusion Criteria:

          1. Major surgery or radiation therapy within 4 weeks of starting the study treatment.

          2. History of or known carcinomatous meningitis, or evidence of symptomatic
             leptomeningeal disease on screening CT or MRI scan.

          3. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2.

          4. Pregnancy or breastfeeding.

          5. Prior exposure to the study drug.

          6. Patients unable to swallow oral medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Cancer Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2010</study_first_submitted>
  <study_first_submitted_qc>April 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2010</study_first_posted>
  <last_update_submitted>December 28, 2015</last_update_submitted>
  <last_update_submitted_qc>December 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Jeeyun Lee</investigator_full_name>
    <investigator_title>Samsung Medical center</investigator_title>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>refractory</keyword>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

